Rani Therapeutics Holdings Inc (RANI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $60.78M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rani Therapeutics Holdings Inc (RANI) Stock Forecast
Analysts expect Rani Therapeutics Holdings (RANI) to earn -$0.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.81M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 2.6%.
- Fiscal year ending Dec 31, 2026
- -$0.17
- EPS consensus, revenue $6.81M
- Fiscal year ending Dec 31, 2027
- -$0.19
- EPS consensus, revenue $6.63M
- Next report
- Mar 25, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.18 to -$0.16 | 4 | $6.81M | $6.80M to $6.83M | 3 |
| Dec 31, 2027 | -$0.19 | -$0.20 to -$0.17 | 4 | $6.63M | N/A | 4 |
Quarterly Estimates
The EPS consensus is -$0.05 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.05 | -$0.06 to -$0.04 | 7 | $1.63M | N/A | 7 |
| Mar 31, 2027 | -$0.05 | -$0.05 to -$0.05 | 1 | N/A | N/A | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.17 | -$0.17 | -$0.17 | -$0.17 | -$0.18 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.19 | -$0.19 | -$0.19 | -$0.19 | -$0.21 | N/A |
Frequently Asked Questions About RANI
What is the RANI stock forecast?
Consensus analyst estimates put Rani Therapeutics Holdings's EPS at -$0.17 for the fiscal year ending Dec 31, 2026, on revenue of $6.81M. The consensus rating from 5 analysts is Buy.
How do analysts rate RANI stock?
Of 5 analysts covering Rani Therapeutics Holdings, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RANI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.17, with estimates from -$0.18 to -$0.16 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.19, with estimates from -$0.20 to -$0.17 from 4 analysts.
What revenue do analysts expect from Rani Therapeutics Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.81M, with estimates from $6.80M to $6.83M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.63M.
How many analysts cover RANI?
5 analysts rate Rani Therapeutics Holdings stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RANI pages: Overview, Earnings, Forecast, Financials, Competitors